By Nina Kienle
Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study.
The German conglomerate on Monday said vericiguat in the phase 3 Victor trial, which compares the efficacy of the drug to placebo in patients with heart failure with reduced ejection fraction, didn't reach statistical significance for its primary endpoint.
In the EU, vericiguat is used for the treatment of symptomatic chronic heart failure in adult patients, Bayer said.
The overall safety profile of vericiguat in the trial was consistent with previous clinical trials, it added.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
September 01, 2025 02:10 ET (06:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.